Platelet signal transduction

Platelet signal transduction is the integrated network of biochemical pathways that regulate platelet activation, shape change, and aggregation in response to vascular damage. This process begins when agonists such as collagen, thrombin, adenosine diphosphate (ADP), and thromboxane A2 bind to their respective transmembrane receptors, including glycoprotein VI, protease-activated receptors (PARs), and P2Y receptors [1][2]. These interactions trigger intracellular signaling cascades involving phospholipase C, protein kinase C, and calcium mobilization, which converge on the activation of the integrin alpha-IIb/beta-3 (GPIIb/IIIa) receptor [3]. Once activated, this receptor binds fibrinogen, facilitating the cross-linking of platelets into a stable thrombus. While essential for normal hemostasis, excessive platelet signaling is a primary driver of pathological thrombosis in cardiovascular diseases like myocardial infarction and ischemic stroke [4]. Consequently, various components of this transduction network serve as critical targets for antiplatelet drugs, which aim to reduce the risk of thrombotic events by dampening platelet reactivity [5]. This entry is classified as incorrect as a single target because it represents a complex biological process involving multiple distinct molecular targets rather than a single therapeutic entity.

Other names

Platelet activation pathwayPlatelet signaling cascadeThrombocyte activationPlatelet aggregation signaling

Inhibition of specific molecular components within the platelet signaling network, such as cyclooxygenase-1 (COX-1), P2Y12 purinergic receptors, protease-activated receptor-1 (PAR-1), or glycoprotein IIb/IIIa receptors, to prevent platelet activation and subsequent thrombus formation.